165 related articles for article (PubMed ID: 32576444)
1. Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib.
Chen X; Zhao G; Zhong P; Zhang M; Chen R; Zhang D
Clin Lung Cancer; 2020 Nov; 21(6):e564-e566. PubMed ID: 32576444
[No Abstract] [Full Text] [Related]
2. Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.
Luo J; Gu D; Lu H; Liu S; Kong J
J Thorac Oncol; 2019 Dec; 14(12):e266-e268. PubMed ID: 31757376
[No Abstract] [Full Text] [Related]
3. A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.
Fei X; Zhu L; Zhou H; Qi C; Wang C
J Thorac Oncol; 2019 Sep; 14(9):e191-e193. PubMed ID: 31445731
[No Abstract] [Full Text] [Related]
4. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
He Z; Wu X; Ma S; Zhang C; Zhang Z; Wang S; Yu S; Wang Q
Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
[No Abstract] [Full Text] [Related]
5. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
[TBL] [Abstract][Full Text] [Related]
6. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
Wu X; Wang W; Zou B; Li Y; Yang X; Liu N; Ma Q; Zhang X; Wang Y; Li D
Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
[TBL] [Abstract][Full Text] [Related]
7. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
[TBL] [Abstract][Full Text] [Related]
8. Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
Wang YL; Wu ZZ; Zhang HR; Chen DS; Zhao X
Lung Cancer; 2021 Apr; 154():216-218. PubMed ID: 33637344
[No Abstract] [Full Text] [Related]
9. Melanoregulin-Anaplastic Lymphoma Kinase (ALK), a Novel ALK Rearrangement That Responds to Crizotinib in Lung Adenocarcinoma.
Wang L; Yao S; Teng L; Zhang W; Chen L
J Thorac Oncol; 2020 Mar; 15(3):e44-e46. PubMed ID: 32093861
[No Abstract] [Full Text] [Related]
10. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma.
Wang L; Li L; Zhou X; Zhang D
Lung Cancer; 2024 May; 191():107797. PubMed ID: 38669726
[No Abstract] [Full Text] [Related]
12. A novel SETD3-ALK fusion in lung adenocarcinoma and sustained clinical response to crizotinib.
Dai S; Liu XQ; Wu Q; Du CM; Liu Q; Xue YY; Luo F; Li Y
Lung Cancer; 2023 Jan; 175():121-124. PubMed ID: 36495785
[TBL] [Abstract][Full Text] [Related]
13. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
[TBL] [Abstract][Full Text] [Related]
14. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
Vendrell JA; Taviaux S; Béganton B; Godreuil S; Audran P; Grand D; Clermont E; Serre I; Szablewski V; Coopman P; Mazières J; Costes V; Pujol JL; Brousset P; Rouquette I; Solassol J
Sci Rep; 2017 Oct; 7(1):12510. PubMed ID: 28970558
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
Zeng L; Xia C; Zhang Y; Yang N
J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
[No Abstract] [Full Text] [Related]
16. Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib.
Zhao G; Chen L; Xiao M; Yang S
Lung Cancer; 2021 Feb; 152():189-192. PubMed ID: 33419583
[No Abstract] [Full Text] [Related]
17. MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.
Fang W; Gan J; Hong S; Lu F; Zhang L
J Thorac Oncol; 2019 Jul; 14(7):e148-e151. PubMed ID: 31235041
[No Abstract] [Full Text] [Related]
18. A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.
Li M; Tang Q; Chen S; Wang Y
Lung Cancer; 2021 Jan; 151():98-100. PubMed ID: 33280926
[No Abstract] [Full Text] [Related]
19. Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.
Mattar MS; Chang J; Benayed R; Halpenny D; Powers A; Kleiner DE; Drilon A; Kris MG
Clin Lung Cancer; 2020 Jan; 21(1):e25-e29. PubMed ID: 31690489
[No Abstract] [Full Text] [Related]
20. A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report.
Guo J; Shi J; Yao M; Jin Y; Liu D; Liu W; Wang K; Jiang D
Medicine (Baltimore); 2020 Nov; 99(45):e22631. PubMed ID: 33157918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
